September 24, 2024 – Vientiane, Laos – Recently, Laos BIGBEAR Pharmaceutical announced that it has obtained official permission from the Lao Ministry of Health. Its anti-cancer drug Mitotane (trade name MITODX) was exported to Malaysia for the first time, achieving a “zero” breakthrough in the Lao pharmaceutical industry!
- Lao pharmaceutical industry exports anti-cancer drugs for the first time!
- Lao pharmaceutical industry exports orphan drugs for the first time!
MITODX’s successful entry into the international market indicates that Laos BIGBEAR Pharmaceutical has been recognized by international customers, and also indicates that the Laos pharmaceutical industry has stepped onto a new level of quality and efficiency improvement. Laos BIGBEAR Pharmaceutical’s export approval and successful completion of trade this time means that the drug has also brought new treatment options to ASEAN patients.
About MITODX (Mitotane)
MITODX (Mitotane) is an adrenocortical inhibitor that inhibits the production of corticosteroids by the adrenal cortex. Studies on the mode of action of mitotane have found that the drug has two main biological effects: first, mitotane can have a direct cytotoxic effect on adrenal cortical cells through mitochondrial changes and inhibition of sterol-O-acyltransferase 1 (SOAT1) activity; second, it inhibits corticosteroid synthesis by changing the peripheral metabolism of cortisol and directly inhibiting the secretion of corticosteroids by the adrenal cortex.
Mitotane is used to treat adreocortical carcinoma, but due to the small number of patients with this disease, it is sold as an orphan drug for the treatment of adrenocortical carcinoma. The drug is sometimes also used to treat Cushing’s syndrome.
About Orphan Drugs
Orphan drugs are also known as rare drugs, which are used to prevent, treat and diagnose rare diseases. Due to the small number of patients with rare diseases, low market demand and high R&D costs, few pharmaceutical companies pay attention to the research and development of their therapeutic drugs, so these drugs are vividly called “orphan drugs”.
About RxLibra
RxLibra is a pharmaceutical industry service provider established in Vientiane, Laos during the COVID-19 pandemic. Its purpose is to help the Lao pharmaceutical industry enter the economic cycle of the global market. Laos is one of the least developed countries in the world and enjoys the WTO’s drug patent control exemption. In the past few years, some pharmaceutical companies from India, China and Bangladesh have entered Laos to set up production bases, introduce technical talents from neighboring countries, and build production workshops that meet GMP standards. These start-up pharmaceutical companies hope to gradually enter the global market. RxLibra plays a similar role as a carrier in this process, responsible for promoting pharmaceutical companies in the early stages of development.
About BIGBEAR Pharmaceuticals
BigBear Pharmaceuticals is headquartered in Vientiane, the capital of Laos. The company is committed to drug research and development, production and sales, and provides high-quality, safe and effective drug products. BigBear Pharmaceuticals has established a good reputation in the Lao pharmaceutical market with its outstanding expertise and innovation capabilities, and actively participates in international pharmaceutical cooperation and exchanges.
Reference from : Double “zero” breakthrough! Laos BIGBEAR Pharmaceutical’s anti-cancer drugs are exported to ASEAN economies for the first time https://www.bigbearpharma.com/en/newsroom/339.html
Comments are closed